Mariner
ARQT icon

Mariner’s Arcutis Biotherapeutics ARQT Stock Holding History

Mariner’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Sell
12,809
-10,965
-46% -$255K ﹤0.01% 2755
2026
Q1 		$560K Sell
23,774
-2,497
-10% -$63.7K ﹤0.01% 2406
2025
Q4 		$762K Buy
26,271
+10,805
+70% +$277K ﹤0.01% 2141
2025
Q3 		$292K Buy
15,466
+5,123
+50% +$80.8K ﹤0.01% 2837
2025
Q2 		$145K Buy
+10,343
New +$145K ﹤0.01% 3156
2025
Q1 		– Sell
-10,028
Closed -$140K – 3444
2024
Q4 		$140K Sell
10,028
-180
-2% -$1.97K ﹤0.01% 3106
2024
Q3 		$94.9K Sell
10,208
-518
-5% -$5.11K ﹤0.01% 3101
2024
Q2 		$99.8K Sell
10,726
-7,079
-40% -$64K ﹤0.01% 2956
2024
Q1 		$176K Buy
+17,805
New +$133K ﹤0.01% 2804

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mariner's ARQT Position: Q2 2026 in Review

Mariner reduced its Arcutis Biotherapeutics (ARQT) stake by 46% in Q2 2026, selling an estimated $255K and leaving 12,809 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #2755.

Mariner first reported a position in ARQT in Q1 2024 and has held it in 9 quarters since. The position peaked at $762K in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Mariner held 12,809 shares of Arcutis Biotherapeutics worth $336K as of Q2 2026.
  • Mariner sold 10,965 Arcutis Biotherapeutics shares in Q2 2026, an estimated $255K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2755 holding.
  • Mariner first reported a position in Arcutis Biotherapeutics in Q1 2024 and has held it in 9 quarters since.
  • Mariner's Arcutis Biotherapeutics position peaked at $762K in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.